Artivion, Inc. (NYSE:AORT) Receives $49.11 Consensus Price Target from Analysts

Shares of Artivion, Inc. (NYSE:AORT) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $49.1143.

A number of research analysts have recently issued reports on the stock. Citizens Jmp lifted their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Citigroup reiterated an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Wall Street Zen upgraded Artivion from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, Needham & Company LLC lifted their target price on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th.

Artivion Trading Down 0.7%

NYSE AORT opened at $46.51 on Friday. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. Artivion has a 52 week low of $21.97 and a 52 week high of $48.04. The business has a 50 day moving average price of $43.47 and a 200-day moving average price of $37.42. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -110.74 and a beta of 1.65.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Jean F. Holloway sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $46.18, for a total transaction of $461,800.00. Following the transaction, the senior vice president directly owned 169,169 shares of the company’s stock, valued at $7,812,224.42. This trade represents a 5.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO James P. Mackin sold 34,210 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.86, for a total transaction of $1,568,870.60. Following the completion of the sale, the chief executive officer directly owned 800,993 shares of the company’s stock, valued at $36,733,538.98. The trade was a 4.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 191,703 shares of company stock valued at $8,669,234 over the last quarter. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Artivion

Several hedge funds have recently modified their holdings of AORT. Aster Capital Management DIFC Ltd grew its holdings in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Artivion in the third quarter worth $27,000. Smartleaf Asset Management LLC grew its stake in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the period. State of Wyoming purchased a new stake in shares of Artivion during the 3rd quarter valued at $80,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Artivion during the 3rd quarter worth $92,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.